Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Vilon

KE, L-Lys-L-Glu, lysylglutamic acid

Quick Stats
Studies 40
Trials 100
Unknown OBSERVATIONAL NCT05439369

Natriuretic Peptides as a Prognostic and Risk Stratification Tool in Assessment of Valvular Heart Disease

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

NPs can be used To detect subset of asymptomatic with subtle LV dysfunction for further evaluation and earlier referral for intervention and its correlation with echocardiographic finding.

Detailed Description

Each patient included in the study will undergo: 1. History taking: Analysis of patient symptoms and signs (dyspnea , orthopnea , Paroxysmal nocturnal dyspnea, lower limb edema , tachypalpitations,…etc ) 2. Clinical examination: * Detecion of each patient body weight , height , calculation of BMI. * General examination for detection of signs of Heart failure (raised JVP , lower limb edema, ..etc) * Examination to respiratory system * Auscultation of the heart for detection of valvular affection before echocardiography Invesigations: Laboratory investigations: Urea and creatinine . b) ECG : for exclusion of atrial fibrillation and other arrythmias. 2D Transthorathic Echocardiography (TTE) Evaluation of valve morphology and thickness , gradients and valve area , regurgitant lesions and its severity. Evaluation of internal cardiac dimensions and function. 5- Natriuretic peptides: as a useful screening tool to differentiate symptomatic and asymptomatic patients.

Primary Outcomes

Measure: early detection of subclinical LV dysfunction.
TimeFrame: 1 year
Description: early detection of subclinical LV dysfunction.

Trial Information

NCT ID

NCT05439369

Status

Unknown

Study Type

OBSERVATIONAL

Sponsor

Assiut University

Last Updated

December 15, 2025